AURA
Aura Biosciences, Inc.
Biotechnology · Healthcare · United States
6.14
close · 2026-10-30
value
60
cheaper than peers60
quality
22
stronger fundamentals22
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -31.9% | 59 |
| cash flow yield, latest year | -13.4% | 58 |
| cash flow yield, 2 years ago | -10.1% | 58 |
| price to book | 2.02× | 57 |
| cash flow yield, 3 years ago | -8.7% | 56 |
| cash flow yield, 1 year ago | -12.7% | 55 |
| earnings yield, 2 years ago | -31.4% | 55 |
| earnings yield, 1 year ago | -28.5% | 50 |
| earnings yield, latest year | -28.7% | 49 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 15.8% | 33 |
| return on equity | -95.6% | 27 |
3 of 4 measures available
Facts
| market cap | $637M |
| free cash flow | -$51.6M |
| employees | 113 |
| first trade | 2021-10-29 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.76 | -1.75 | -1.93 | -1.96 | not reported |
| free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M | not reported |
| net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | $0 | $208,000 | -$318,000 | -$3,000 |